Imagine a child with a mysterious illness, struggling with coordination and vision problems, all linked to a post-COVID inflammatory syndrome. This is the reality for some young patients with Multisystem Inflammatory Syndrome in Children (MIS-C), a condition that can manifest in surprising and alarming ways. But here's where it gets even more intriguing: we're about to explore a rare case where ataxia (loss of coordination) and papilledema (swelling of the optic nerve) occur together, challenging our understanding of this already complex syndrome. And this is the part most people miss: these symptoms, though rare, could be crucial in early diagnosis and treatment, potentially preventing severe complications like permanent vision loss.
MIS-C is a multisystem inflammatory condition affecting individuals under 21, typically presenting with fever, involvement of at least two organs (such as the heart, skin, eyes, or gastrointestinal tract), elevated inflammatory markers, and a history of COVID-19 exposure. While neurological symptoms like headaches and photophobia are relatively common in MIS-C, the simultaneous occurrence of ataxia and papilledema is exceptionally rare. Ataxia, characterized by uncoordinated muscle movements, and papilledema, caused by increased intracranial pressure, are not typically associated with MIS-C, making this case particularly noteworthy.
Consider a 13-year-old Iranian boy from a deprived area, admitted to Namazi Hospital in Shiraz, Iran, in May 2022. He presented with fever, widespread skin rashes, palmar erythema, vomiting, and diarrhea. Additionally, he exhibited severe conjunctivitis, photophobia, headaches, and ataxia. Despite initial negative COVID-19 PCR and IgM tests, his serum IgG was positive, suggesting a recent SARS-CoV-2 infection. The patient's condition involved three major organ systems—the brain, skin, and gastrointestinal tract—prompting a diagnosis of MIS-C. Brain imaging revealed papilledema and flattening of the posterior globe, while lumbar puncture showed elevated opening pressure, consistent with increased intracranial pressure. Treatment with high-dose methylprednisolone, intravenous immunoglobulin, and other supportive therapies led to significant improvement, with resolution of ataxia, headache, and papilledema within 10 days.
But here's the controversial part: Could MIS-C directly cause such high intracranial pressure, or is it a result of treatment complications? Some argue that immunomodulatory treatments might contribute to these symptoms, but in this case, methylprednisolone was administered after the lumbar puncture, suggesting MIS-C itself could be the culprit. This raises important questions about the pathophysiology of MIS-C and its impact on the central nervous system. Are we missing other rare neurological manifestations in these patients? How can we better identify and manage these cases to prevent long-term complications?
This case highlights the importance of recognizing rare neurological presentations of MIS-C, such as ataxia and papilledema. Early diagnosis and prompt treatment are crucial to prevent severe outcomes like permanent vision loss. Physicians should maintain a high index of suspicion for these symptoms in MIS-C patients, especially when other organ systems are involved. What do you think? Is enough being done to investigate and manage these rare neurological complications of MIS-C? Share your thoughts in the comments below, and let's spark a discussion on how we can improve care for these vulnerable patients.
